866-997-4948(US-Canada Toll Free)

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Apr 2015

Category :

Bladder Cancer

No. of Pages : 100 Pages

 

Global Markets Directs, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Review, H1 2015, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)s therapeutic pipeline.

 

This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents


Table of Contents 2
List of Tables 5
List of Figures 6
 

Introduction 7
Global Markets Direct Report Coverage 7
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 8
Therapeutics Development 9
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview 9
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis 10
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies 11
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Investigation by Universities/Institutes 12
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies 16
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Investigation by Universities/Institutes 18
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development 19
Altor BioScience Corporation 19
Bavarian Nordic A/S 20
Cold Genesys, Inc. 21
Heat Biologics, Inc. 22
Marina Biotech, Inc. 23
Oncogenex Pharmaceuticals, Inc. 24
Spectrum Pharmaceuticals, Inc. 25
TARIS BioMedical, Inc. 26
Telesta Therapeutics Inc. 27
Vakzine Projekt Management GmbH 28
Viralytics Ltd. 29
Viventia Biotechnologies Inc. 30
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
ALT-801 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ALT-803 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
apatorsen - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
apaziquone - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
APL-1202 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Biologic for Superficial Bladder Cancer - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CG-0070 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CV-301 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CVA-21 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DAB-389EGF - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drug for NMIBC - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MDR-09521 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
oportuzumab monatox - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rAd-IFN - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
sirolimus albumin-bound - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
TD-210 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Urocidin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
vesigenurtucel-L - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
VPM-1002 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Recent Pipeline Updates 74
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects 91
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products 92
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones 93
Featured News & Press Releases 93
Mar 09, 2015: Heat Biologics Receives US FDA Fast Track Designation for HS-410 (Vesigenurtacel L) in Combination With BCG for the Treatment of Non-Muscle Invasive Bladder Cancer 93
Feb 26, 2015: Heat Biologics Provides Update at Key Opinion Leader Event 93
Jan 26, 2015: Heat Biologics Presents Positive Immunological Data on HS-410 in Non-Muscle Invasive Bladder Cancer at the 7th Annual Phacilitate Immunotherapy Forum 2015 94
Dec 01, 2014: Telesta Therapeutics Announces Key Clinical & Corporate Updates 95
Nov 05, 2014: Bioniche Life Sciences provides Orphan Drug Designation Update 95
Aug 04, 2014: Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies 96
Jul 18, 2014: Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States 97
Nov 05, 2012: Bioniche Life Sciences Discontinues Phase III Clinical Trial Of Urocidin 97
Apr 05, 2012: Spectrum Announces Results Of Apaziquone Phase III Clinical Trials 98
Jan 19, 2012: OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium 98


Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

List of Table

 

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2015 9
Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Products under Investigation by Universities/Institutes, H1 2015 18
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Altor BioScience Corporation, H1 2015 19
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Bavarian Nordic A/S, H1 2015 20
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Cold Genesys, Inc., H1 2015 21
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Heat Biologics, Inc., H1 2015 22
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Marina Biotech, Inc., H1 2015 23
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 24
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 25
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by TARIS BioMedical, Inc., H1 2015 26
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Telesta Therapeutics Inc., H1 2015 27
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vakzine Projekt Management GmbH, H1 2015 28
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viralytics Ltd., H1 2015 29
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viventia Biotechnologies Inc., H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Recent Pipeline Updates, H1 2015 74
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects, H1 2015 91
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products, H1 2015 92

List of Chart

 

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2015 9
Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Top 10 Targets, H1 2015 32
Number of Products by Stage and Top 10 Targets, H1 2015 32
Number of Products by Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Top 10 Routes of Administration, H1 2015 36
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37
Number of Products by Top 10 Molecule Types, H1 2015 38
Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *